Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals Announces the Presentation of Data at Several Upcoming Scientific Meetings
05/09/2012| 12:35pm US/Eastern
Recommend:
- Clinical trial data from oncology and Alzheimer's disease
product candidates to be presented -
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty
pharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that data from its Phase 3
clinical studies investigating Lymphoseek® (Kit for the Preparation of
Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer,
breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of
its Alzheimer's Disease candidate, AZD4694, were accepted for
presentation at several upcoming scientific and medical meetings in May.
Details of the presentations are listed below.
|
|
|
Conference: European Society for Therapeutic Radiology and
Oncology
|
|
Dates: May 9-13
|
|
Location: Barcelona, Spain
|
|
Author: 1. Frederick O. Cope, PhD; 2. Wendy L. Metz, PhD, Navidea
Biopharmaceuticals
|
|
Presenter: Michael S. Blue, MD, Navidea Biopharmaceuticals
|
|
Presentation Titles:
|
|
1. Tc99m Tilmanocept, A CD206 ILM Agent, Has >24 Hour Stability
in Nodes and Concordance with Imaging in Breast Cancer
|
|
2. Correlation of Lymphoscintigraphy with Intraoperative
Lymphatic Mapping in Phase 3 with Tc99m Tilmanocept in Breast
Cancer and Melanoma
|
|
|
|
Conference: 12th International
Stockholm/Springfield Symposium on Advances in Alzheimer Therapy
|
|
Dates: May 9-12
|
|
Location: Stockholm, Sweden
|
|
Author: Zsolt Cselényi, AstraZeneca, Södertälje, Sweden
|
|
Presentation Title:
|
|
1. Early clinical development of amyloid-beta specific PET
radioligand [18F]AZD4694
|
|
|
|
Conference: Australasian Lymphology Association
|
|
Dates: May 24-26
|
|
Location: Queensland, Australia
|
|
Author: Wendy L. Metz, PhD
|
|
Presentation Title:
|
|
1. Estimation of intra-surgical sentinel lymph node mapping
performance parameters of 99mTc-tilmanocept in melanoma and other
solid tumors utilizing in vitro modeling with fluorescent
Cy3-tilmanocept; alteration of mannose moiety configuration
binding to human lymph node macrophages and the CD206 receptor
|
|
|
|
Conference: International Symposium on Sentinel Node Biopsy in
Head and Neck Cancer
|
|
Dates: May 24-25
|
|
Location: Amsterdam, the Netherlands
|
|
Author: Stephen Y. Lai, MD, PhD, FACS, University of Texas M.D.
Anderson Cancer Center
|
|
Presentation Title:
|
|
1. Detection of Sentinel Lymph Nodes in Cutaneous and Intraoral
Head and Neck Squamous Cell Carcinoma with 99m-Tc-Tilmanocept:
Clinical Experience at M.D. Anderson Cancer Center
|
|
|
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is actively developing three radiopharmaceutical agent
platforms - Lymphoseek®, AZD4694 and RIGScanTM -
to help identify the sites and pathways of undetected disease and enable
better diagnostic accuracy, clinical decision-making and ultimately
patient care. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company's pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson,
614-822-2330
Sr. VP & CFO
© Business Wire 2012
Recommend :
